

Engineered by nature

+ Available on-demand

Our Cellular and/or Tissue-Based Products (CTPs), including our Porcine Small Intestinal Submucosa lineup and our Placental Tissue collection, are designed with preservation in mind

Smith+Nephew


GrafixPL 
Lyopreserved Placental Membrane

Grafix 
Cryopreserved Placental Membrane

Stravix 
Cryopreserved Umbilical Tissue

OASIS 
Matrix Products

OASIS  **MICRO**
Micronized Wound Matrix



Preserved with care + Superior clinical evidence

All of Smith+Nephew's CTPs retain the complex extracellular matrix of the tissues from which they're derived. Native growth factors and viable cells are additionally preserved within GrafixPL^o, Grafix^o, and Stravix^o. Unlike other products made of just type I collagen, these CTPs closely mimic human skin.¹⁻²¹

Components		Human skin	GrafixPL/ Grafix	Stravix	OASIS ^o / OASIS MICRO
Extracellular matrix	structural proteins	✓	✓	✓	✓
	GAGs	✓	✓	✓	✓
	glycoproteins	✓	✓	✓	✓
	proteoglycans	✓	✓	✓	✓
Growth factors (GFs) and other mediators*	bFGF	✓	✓	✓	
	VEGF	✓	✓	✓	
	PDGF	✓	✓	✓	
	IL-10	✓	✓	✓	
	IL-1RA	✓	✓	✓	
	TIMPs	✓	✓	✓	
	TGF - β 1 & β 3	✓	✓	✓	
	HGF	✓	✓	✓	
Viable cells	N-Gal	✓	✓	✓	
	mesenchymal stem cells	✓	✓	✓	
	fibroblasts	✓	✓	✓	
	epithelial cells	✓	✓	✓	

*List not inclusive of all growth factors

Placental Tissue Products: Lyopreserved or cryopreserved placental tissue composed of native viable cells, growth factors, and extracellular matrix

Small Intestinal Submucosa (SIS) Products:

Natural extracellular matrices that support the migration of cells and the ingrowth of blood vessels

Proven results in over




600 clinical publications







11 wound randomized controlled trials²²⁻³²

No matter the size, Smith+Nephew's CTPs have you covered.


Stravix[◇]
Cryopreserved
Umbilical Tissue



OASIS[®]
Matrix Products



OASIS[®] MICRO
Micronized Wound Matrix



CTPs for all your wound care and surgical needs

Product	Common outpatient usage
GrafixPL [◊] /Grafix [◊] OASIS [®]	Cover for hard-to-treat acute and chronic wounds including diabetic foot ulcers and venous/arterial ulcers
Product	Common inpatient usage
GrafixPL/Grafix Stravix [◊]	Cover for complex wounds with exposed structures, wrap for tendon/bone/nerve repair site, barrier under incisions
OASIS	Cover for large wounds (such as trauma wounds, burns, donor sites)
OASIS MICRO	Filler for tunneling wounds and deeper wounds with crevices

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's instructions for use prior to use.

Contraindications: OASIS Matrix products are derived from a porcine source and should not be used in patients with known sensitivity to porcine material. OASIS Matrix products are not indicated for use in third-degree burns.

References: 1. Dhall S, Sathyamoorthy M, Kuang JQ, et al. Properties of viable lyopreserved amnion are equivalent to viable cryopreserved amnion with the convenience of ambient storage. *PLoS One*. 2018; 13(10): e0204060. 2. Data on file at Osiris Therapeutics, Inc. 3. Niknejad H, Peirovi H, Jorjani M, et al. Properties of the amniotic membrane for potential use in tissue engineering. *Eur Cells Mater*. 2008; 15: 88-99. 4. Koizumi NJ, Inatomi TJ, Sotozono CJ, et al. Growth factor mRNA and protein in preserved human amniotic membrane. *Curr Eye Res*. 2000; 20:173-177. 5. Vaculik C, Schuster C, Bauer W, et al. Human dermis harbors distinct mesenchymal stromal cell subsets. *J Invest Dermatol*. 2012; 132(3 Pt 1): 563-74. 6. Badylak SF. The extracellular matrix as a scaffold for tissue reconstruction. *Semin Cell Dev Biol*. 2002; 13(5): 377-383. 7. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. *J Cell Sci*. 2010; 123(24): 4195-4200. 8. Internal Cook Biotech Document: 97-010 VIIA. 9. Internal Cook Biotech Document: 97-010 VIIB. 10. Internal Cook Biotech Document: 07-057. 11. Internal Cook Biotech Document: 00-027. 12. Internal Cook Biotech Document: 98-084. 13. Brown B, Lindberg K, Reing J, Stolz DB, Badylak SF. The basement membrane component of biologic scaffolds derived from extracellular matrix. *Tissue Eng*. 2006; 12(3): 519-526. 14. Hodde JP, Badylak SF, Brightman AO, Voytyk-Harbin SL. Glycosaminoglycan content of small intestinal submucosa: a bioscaffold for tissue replacement. *Tissue Eng*. 1996; 2(3): 209-217. 15. Hodde JP, Janis A, Ernst D, Zopf D, Sherman D, Johnson C. Effects of sterilization on an extracellular matrix scaffold: Part 1. Composition and matrix architecture. *J Mater Sci Mater Med*. 2007; 18(4): 537-543. 16. Internal Cook Biotech Document: 96-006. 17. Hurst RE, Bonner RB. Mapping of the distribution of significant proteins and proteoglycans in small intestinal submucosa by fluorescence microscopy. *J Biomater Sci Polym Ed*. 2001; 12(11): 1267-1279. 18. Kinn PM, Holdren GO, Westermeyer BA, et al. Age-dependent variation in cytokines, chemokines, and biologic analytes rinsed from the surface of healthy human skin. *Sci Rep*. 2015; 5: 10472. doi: 10.1038/srep10472. 19. Son ED, Lee JY, Lee S, et al. Topical application of 17beta-estradiol increases extracellular matrix protein synthesis by stimulating tgf-Beta signaling in aged human skin in vivo. *J Invest Dermatol*. 2005; 124(6): 1149-61. 20. Kabelitz D, Schröder J-M (eds): Mechanisms of Epithelial Defense. Chem Immunol Allergy. Basel, Karger, 2005, vol 86, pp 22-41. 21. McGrath JA, Eady RAJ, Pope FM. Anatomy and organization of human skin. In Burns T, Breathnach S, Cox N, Griffiths C, editors, Rook's Textbook of Dermatology. Oxford: Blackwell Science Ltd Oxford. 2004. p. 3.1 - 3.84. 22. Lavery LA, Fulmer J, Shebetka KA, et al. The efficacy and safety of Grafix[®] for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. *Int Wound J*. 2014; 11(5): 554-560. 23. Cazzell SM, Lange DL, Dickerson JE, et al. The management of diabetic foot ulcers with porcine Small Intestine Submucosa Tri-Layer Matrix: A randomized controlled trial. *Adv Wound Care*. 2015; 4(12): 711-718. 24. Landsman A, Roukis TS, DeFronzo DJ, et al. Living cells or collagen matrix: Which is more beneficial in the treatment of diabetic foot ulcers? *Wounds*. 2008; 20(5): 111-116. 25. Mostow EN, Haraway GD, Dalsing M, et al. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. *J Vasc Surg*. 2005; 41(5): 837-843. 26. Romanelli M, Dini V, Bertone MS. Randomized comparison of OASIS wound matrix versus moist wound dressing in the treatment of difficult-to-heal wounds of mixed arterial/venous etiology. *Adv Skin Wound Care*. 2010; 23(1): 34-38. 27. Brown-Etris M, Milne C, Hodde J. An extracellular matrix graft (OASIS wound matrix) for treating full-thickness pressure ulcers: A randomized clinical trial. *J Tissue Viability*. 2019; 28(1): 21-26. 28. Baldursson BT, Kjartansson H, Konradsdottir F, et al. Healing rate and autoimmune safety of full-thickness wounds treated with fish skin acellular dermal matrix versus porcine small-intestine submucosa: a noninferiority study. *Int J Low Extrem Wounds*. 2015; 14(1): 37-43. 29. Romanelli M, Dini V, Bertone M, et al. OASIS wound matrix versus Hyaloskin in the treatment of difficult-to-heal wounds of mixed arterial/venous aetiology. *Int Wound J*. 2007; 4(1): 3-7. 30. Tchanque-Fossou CN, Dahle SE, Lev-Tov H, et al. Cellular versus acellular matrix devices in the treatment of diabetic foot ulcers: interim results of a comparative efficacy randomized controlled trial. *J Tissue Eng Regen Med*. 2019; 13 (8):1430-1437. 31. Niezgoda JA, Van Gils CC, Frykberg RG, et al. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. *Adv Skin Wound Care*. 2005; 18(5): 258-66. 32. Mari W, Younes S, Naqvi J, et al. Use of a natural porcine extracellular matrix with negative pressure wound therapy hastens the healing rate in stage 4 pressure ulcers. *Wounds*. 2019; 31(5): 117-122.

Advanced Wound Management
Smith & Nephew, Inc.
Fort Worth, TX 76109 USA

GrafixPL, Grafix & Stravix
Customer Care Center:
T 888-674-9551
F 443-283-4419

OASIS Customer Care Center:
T 1-800-876-1261
F 727-392-6914

◊Osiris, Grafix, GrafixPL, Grafix PRIME, Grafix CORE, Grafix XC, GrafixPL PRIME, and Stravix are trademarks of Osiris Therapeutics, Inc., a wholly owned direct subsidiary of Smith & Nephew Consolidated, Inc. OASIS is a registered trademark of Cook Biotech, Inc.

©2020 Smith+Nephew, Inc.
GRPE6-22545-0220
www.smith-nephew.com
www.osiris.com
www.oasiswoundmatrix.com

OASIS Matrix products are manufactured by:
Cook Biotech, Inc.
1425 Innovation Place
West Lafayette, IN 47906

OASIS Matrix products are distributed by:
Advanced Wound Management
Smith & Nephew, Inc.
Fort Worth, TX 76109